Amundi
CORT icon

Amundi’s Corcept Therapeutics CORT Stock Holding History

Amundi’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$848K Sell
9,751
-1,641
-14% -$99.1K ﹤0.01% 1446
2026
Q1 		$459K Buy
+11,392
New +$426K ﹤0.01% 1576
2025
Q4 		– Sell
-5,766
Closed -$518K – 1852
2025
Q3 		$518K Hold
5,766
– – ﹤0.01% 1319
2025
Q2 		$411K Buy
5,766
+1,827
+46% +$132K ﹤0.01% 1428
2025
Q1 		$313K Buy
+3,939
New +$240K ﹤0.01% 1591
2024
Q1 		– Sell
-5,981
Closed -$150K – 2008
2023
Q4 		$150K Hold
5,981
– – ﹤0.01% 1697
2023
Q3 		$165K Buy
+5,981
New +$173K ﹤0.01% 1641
2023
Q2 		– Sell
-13,263
Closed -$289K – 2049
2023
Q1 		$289K Buy
+13,263
New +$291K ﹤0.01% 1477

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Amundi's CORT Position: Q2 2026 in Review

Amundi reduced its Corcept Therapeutics (CORT) stake by 14% in Q2 2026, selling an estimated $99.1K and leaving 9,751 shares worth $848K. The position accounts for ﹤0.01% of the portfolio, ranked #1446.

Amundi first reported a position in CORT in Q1 2023 and has held it in 8 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Amundi held 9,751 shares of Corcept Therapeutics worth $848K as of Q2 2026.
  • Amundi sold 1,641 Corcept Therapeutics shares in Q2 2026, an estimated $99.1K.
  • Corcept Therapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1446 holding.
  • Amundi first reported a position in Corcept Therapeutics in Q1 2023 and has held it in 8 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.